1. Home
  2. DAKT vs GERN Comparison

DAKT vs GERN Comparison

Compare DAKT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

HOLD

Current Price

$20.41

Market Cap

964.5M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.42

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAKT
GERN
Founded
1968
1990
Country
United States
United States
Employees
N/A
229
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
964.5M
1.1B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
DAKT
GERN
Price
$20.41
$1.42
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
247.7K
14.8M
Earning Date
03-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.75
N/A
Revenue
$608,932,000.00
N/A
Revenue This Year
$12.06
$26.91
Revenue Next Year
$9.16
$43.75
P/E Ratio
$26.71
N/A
Revenue Growth
6.89
N/A
52 Week Low
$13.05
$1.04
52 Week High
$28.27
$2.01

Technical Indicators

Market Signals
Indicator
DAKT
GERN
Relative Strength Index (RSI) 56.93 37.29
Support Level $18.99 $1.24
Resistance Level $21.14 $1.49
Average True Range (ATR) 0.53 0.09
MACD 0.20 -0.01
Stochastic Oscillator 91.91 1.45

Price Performance

Historical Comparison
DAKT
GERN

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: